{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125376","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.071656+00:00","generated_at":"2026-05-30T01:58:48.043460+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort","bullets":["Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.","Q3 operating loss $16.4M vs $18.2M in Q3 2023; R&D expenses $13.8M, G&A $3.8M.","BDC-3042 Phase 1 advanced to 10 mg/kg cohort; data update expected H1 2025.","BDC-4182 on track for clinical trial start in Q2 2025; preclinical data at SITC.","Collaboration revenue $1.1M, down from $2.5M in prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125376","json":"https://secwatch.observer/filing/0000950170-24-125376.json","markdown":"https://secwatch.observer/filing/0000950170-24-125376.md","text":"https://secwatch.observer/filing/0000950170-24-125376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/0000950170-24-125376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/bolt-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:58:48.043460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}